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Abstract 
Background: Refractory central nervous system (CNS) involvement is among the major causes of therapy failure in 
childhood acute leukemia. Applying contemporary diagnostic methods, CNS disease is often underdiagnosed. To 
explore more sensitive and less invasive CNS status indicators, we examined microRNA (miR) expressions and extracel-
lular vesicle (EV) characteristics.
Methods: In an acute lymphoblastic leukemia (ALL) discovery cohort, 47 miRs were screened using Custom TaqMan 
Advanced Low-Density Array gene expression cards. As a validation step, a candidate miR family was further scru-
tinized with TaqMan Advanced miRNA Assays on serial cerebrospinal fluid (CSF), bone marrow (BM) and peripheral 
blood samples with different acute leukemia subtypes. Furthermore, small EV-rich fractions were isolated from 
CSF and the samples were processed for immunoelectron microscopy with anti-CD63 and anti-CD81 antibodies, 
simultaneously.
Results: Regarding the discovery study, principal component analysis identified the role of miR-181-family (miR-
181a-5p, miR-181b-5p, miR-181c-5p) in clustering CNS-positive  (CNS+) and CNS-negative  (CNS‒) CSF samples. We 
were able to validate miR-181a expression differences: it was about 52 times higher in CSF samples of  CNS+ ALL 
patients compared to  CNS‒ cases (n = 8 vs. n = 10, ΔFC = 52.30, p = 1.5E−4), and  CNS+ precursor B cell subgroup also 
had ninefold higher miR-181a levels in their BM (p = 0.04). The sensitivity of CSF miR-181a measurement in ALL highly 
exceeded those of conventional cytospin in the initial diagnosis of CNS leukemia (90% vs. 54.5%). Pellet resulting from 
ultracentrifugation of  CNS+ CSF samples of ALL patients showed atypical  CD63−/CD81− small EVs in high density by 
immunoelectron microscopy.
Conclusions: After validating in extensive cohorts, quantification of miR-181a or a specific EV subtype might provide 
novel tools to monitor CNS disease course and further adjust CNS-directed therapy in pediatric ALL.
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Background
Despite extensive endeavors towards risk-directed treat-
ment, acute leukemia remain the major cause of death 
and is responsible for the highest number of disability-
adjusted life-years in children and adolescents with can-
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system (CNS) represents an outstanding therapeutic 
problem [2]. Prophylactic regimens (intrathecal and 
high-dose systemic chemotherapy, cranial irradiation) 
against CNS leukemia has become a prerequisite of suc-
cessful treatment: prior to the introduction of CNS-
targeted therapy in the 1960s, symptomatic meningeal 
leukemia developed in more than 50% of cases and CNS 
relapse rate was over 65% in childhood acute lympho-
blastic leukemia (ALL) [3, 4]. Nevertheless, patients with 
ALL who have a history of overt CNS involvement at the 
initial diagnosis are still susceptible to relapse with only 
15–20% 5-year survival rates [5]. CNS disease in acute 
myeloid leukemia (AML) entails poor outcomes, and 
optimal treatment has not been established, mainly due 
to the rarity of this condition [6].
According to the modern approach, the CNS invasion 
can be the ultimate step of the tumor cascade [7], and 
vice versa, CNS relapse of acute leukemia constitutes an 
early manifestation of systemic relapse and subclones 
freely traffic between leukemic niches of different organs 
[8]. Thus, neural and bone marrow (BM) compartments 
also need to be monitored to reach proper disease con-
trol. Very sensitive laboratory methods are available to 
monitor minimal residual disease in the BM. Currently 
used tests can quantify the leukemic cells after a fall by 4 
to 6 logs [9]. We lack tools with similar sensitivity regard-
ing the CNS compartment. The most widespread con-
temporary methods for the assessment of cerebrospinal 
fluid (CSF) are conventional cytologic examination of a 
cytocentrifuge smear and flow cytometry [10]. Espe-
cially due to the paucity of cells in the CSF, both methods 
yield a high proportion (more than 40%) of false-negative 
reports among patients with proven CNS infiltration 
by neuroimaging or autopsy [11]. Consequently, a gold 
standard method for staging the CNS involvement in 
acute leukemia has not been established yet.
We hypothesize that some non-cellular biomarkers 
could identify undiagnosed CNS leukemia cases and 
unravel treatment response follow-up in this important 
compartment. MicroRNAs (miRs) belong to the class of 
highly conserved small non-coding RNAs that play key 
regulatory role in a wide range of biological processes 
such as proliferation, differentiation and survival [12]. 
Altered expression patterns of miRs have been increas-
ingly recognized associating with progression in vari-
ous types of tumors including acute leukemia [13]. The 
deregulation of miRs in disease conditions can be har-
nessed as potential new-generation therapeutics.
Cells in the human body continuously discharge large 
amounts of vesicles 30–1000  nm in diameter into the 
extracellular space. Extracellular vesicles (EVs) are impor-
tant factors of intercellular communication: they transfer 
DNA, coding and regulatory RNAs, lipids and proteins 
in the microenvironment as well as among very distant 
tissues [14]. It is widely accepted that EV production 
increases in the tumor microenvironment, hence, these 
particles may facilitate proper “cancer cell biopsy”. In 
studies performed on different leukemia patients, pres-
ence of EVs originating from leukemic cells was shown 
and certain alterations in the EVs correlated with the 
hijacking of disease niches and treatment efficacies [15].
In this study, we provide an analysis of miRs as puta-
tive biomarkers of pediatric acute leukemia stage and 
dynamics in the CNS compartment and a novel pro-
posal of examining small EVs in the CSF of CNS leuke-
mia patients. We based our miR investigation not only on 
CSF but also on bone marrow (BM) and peripheral blood 




Between October 2015 and August 2019, we collected 
peripheral blood, bone marrow (PB and BM, respectively; 
in tubes with 3.2% buffered sodium citrate solution) and 
CSF (native) from 186 consecutive, unselected patients 
(aged ≤ 18 years) diagnosed with acute leukemia or con-
comitant relapse in two Hungarian pediatric hematol-
ogy centers (Semmelweis University 2nd Department of 
Pediatrics and Heim Pal National Pediatric Institute). All 
patients were enrolled into a Berlin-Frankfurt-Münster 
(BFM) trial, and samples were obtained at different time-
points in the 1st month of chemotherapy. Patients under-
went diagnostic and follow-up lumbar puncture (LP). 
CSF was examined in the participating hospital according 
to BFM protocols with the use of a cell counting cham-
ber and conventional cytology after cytocentrifugation. 
For the present study, CNS status was defined as follows, 
with respect to subsequent rate of relapses [16]: CNS-
involved  (CNS+; nontraumatic LP with unambiguously 
identified blasts on cytospin preparation of CSF) and 
CNS-negative  (CNS−; blast-free CSF).  CNS− cases were 
selected based on conventional cytologic preparations 
double-checked by expert pediatric hematologists (com-
ments in Table 1) and the absence of meningeal infiltra-
tion signs by medical imaging and/or clinical neurologic 
examination. Patients with traumatic LP were excluded. 
Preparation of platelet-free plasma (PFP) from PB and 
BM samples was carried out within 2  h of sampling by 
centrifugation at 2500g for 15 min two times [17].
To constitute a discovery cohort, we selected  CNS+ 
ALL patients (n = 4) and matched  CNS− patients at a 
ratio of 1:1 according to sex, age at diagnosis and immu-
nophenotype (Table  1 and Additional file  1: Table  S1). 
Related CSF and PB samples were analyzed. Refer-
ence PB samples were obtained from individuals with 
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non-malignant diseases (n = 10; median age: 4.2; the 
proportion of males: 0.4; diagnoses: vitamin D defi-
ciency, impetigo, otitis media, latent hypothyroidism, 
juvenile idiopathic arthritis, iron deficiency anemia, 
neurofibromatosis type 1, phimosis). Validation cohort 
consisted of ALL, AML or mixed phenotype acute leu-
kemia (MPAL) patients with  CNS+ (n = 11) and  CNS‒ 
(n = 13) diseases (Table 1 and Additional file 1: Table S1). 
Table 1 Clinical characteristics of childhood acute leukaemia patients involved in discovery and validation cohorts
Treatment guidelines: aALL IC BFM 2009, bALL REZ BFM 2002, cInterfant 2006, dAML BFM 98
CNS central nervous system, ALL acute lymphoblastic leukaemia, AML acute myeloid leukaemia, MPAL mixed phenotype acute leukaemia, Rel relapse, CSF 
cerebrospinal fluid, BM bone marrow, PB peripheral blood, WBC white blood cell, RBC red blood cell, d day
Total number of examined samples Samples
Discovery cohort Validation cohort
20 138
Control group (sample type, number of individuals) PB, n = 10 CSF, n = 6
ID Diagnosis, treatment CSF cytology (CNS status according 
to protocol)
CSF CSF BM PB
CNS+ patient group
 P1 ALL, late-onset  Relb lymphoid cells with unambiguous blasts (CNS-2) d0 d0, d15 d0, d15, d30 d0, d15, d30
 P2 ALL, de  novoc 86 WBCs; high amount of blasts (CNS-3) d0, d15 d0, d15, d32, d45 d37 d0, d37
 P3 ALL, de  novoa 1 unambiguous blast, 2 suspicious cells (CNS-2) d0 d0, d15, d33 d0, d15, d33 d0, d15, d33
 P4 ALL, de  novoa 4 WBCs/μl with blasts (CNS-2) d0, d15 ‒ ‒ ‒
 P5 ALL, de  novoa 18 lymphoid cells (mainly blasts), 20 Gumprecht 
shadows (CNS-2)
‒ d0, d15 d0, d15 d0, d15
 P6 ALL, de  novoa 1 unambiguous blast (CNS-2) ‒ d0, d15, d33 d0, d15, d33 d0, d15, d33
 P7 MPAL, de  novoa some cells, 70% blast (CNS-2) ‒ d15, d33 d0, d15, d33 d0, d15, d33
 P8 AML, de  novod 53 cells; 8% blast (CNS-2) ‒ d0, d15 d0 d0, d15
 P9 AML, de  novod 7 WBCs/μl; numerous blasts (CNS-3) ‒ d0, d28 d0, d28 d0, d28
 P10 ALL, early-onset  Relb 43 WBCs, mostly blasts (CNS-3) ‒ d0 d0 ‒
 P11 ALL, de  novoa nucleated cells, 70% blast (CNS-2) ‒ d0, d15 ‒ ‒
 P12 ALL, de  novoa 35 lymphoid cells with 10% blast (CNS-2) ‒ d0, d15, d26, d40 ‒ ‒
CNS− patient group
 P13 ALL, de  novoa 1 cell/μl without blasts (CNS-1) d0 ‒ ‒ ‒
 P14 ALL, de  novoa without cells (CNS-1) d0 ‒ ‒ ‒
 P15 ALL, de  novoa without cells (CNS-1) d0 ‒ ‒ ‒
 P16 ALL, de  novoa 1 cell/μl without blasts (CNS-1) d0 ‒ ‒ ‒
 P17 ALL, early-onset  Relb squamous cells, 2 lymphocyte, 1 Gumprecht 
shadow (CNS-1)
‒ d0, d15 d0, d15, d37 d0, d15, d37
 P18 ALL, early-onset  Relb without cells (CNS-1) ‒ d0, d15 d0, d15 d0, d15
 P19 ALL, de  novoa without cells (CNS-1) ‒ d0, d15, d33 d0, d15, d33 d0, d15, d33
 P20 ALL, de  novoa only a few RBCs (CNS-1) ‒ d0, d15 d0, d15, d33 d0, d15, d33
 P21 ALL, de  novoa 2 cells without blasts (CNS-1) ‒ d0, d15, d33 d0, d15, d33 d0, d15, d33
 P22 MPAL, de  novoa a few squamous cells on cytospin (CNS-1) ‒ d15, d38 d0, d15, d38 d0, d15, d38
 P23 AML, de  novod some RBCs without blasts (CNS-1) ‒ d0 d0, d23 d0, d15, d23
 P24 AML, de  novod 1 segmented, 2 band neutrophil granulocytes 
(CNS-1)
‒ d0, d28 d0, d15, d28 d28
 P25 ALL, de  novoa 1 segment, 8 WBC (CNS-1) ‒ d0 d0 ‒
 P26 ALL, de  novoa without cells (CNS-1) ‒ d0 ‒ ‒
 P27 ALL, de  novoa without cells (CNS-1) ‒ d0 ‒ ‒
 P28 ALL, de  novoa 4 segmented neutrophil cells, 3 lymphocytes, 1 
monocyte, 1 Gumprecht shadow, but no blasts 
(CNS-1)
‒ d0 ‒ ‒
 P29 ALL, de  novoa without cells (CNS-1) ‒ d0 ‒ ‒
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In this cohort, median follow-up time of patients after 
involving them into this study was 1.4  years (range 
0.1‒3.3). Analysis was performed on CSF, BM and PB 
samples. Reference CSF samples in the validation study 
were derived from spinal muscular atrophy (SMA) 
patients (n = 6, median age: 1.34, proportion of males: 
0.8).
RNA isolation and cDNA amplification
Total RNA was isolated from BM PFP, PB PFP and 
human native CSF samples using the miRNeasy Serum/
Plasma Mini Kit (Qiagen, Hilden, Germany), according 
to the manufacturer’s instructions with an initial volume 
of 100  μl. RNA was eluted into 12  μl RNase-free water 
and 1.2  μl RNase Inhibitor (Thermo Fisher Scientific, 
Waltham, MA, USA) was added per sample, then stored 
at − 80 °C. Synthesis of cDNA by universal reverse tran-
scription chemistry after 3′ poly-A tailing and 5′ liga-
tion was performed with a TaqMan Advanced miRNA 
cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, 
MA, USA) following the manufacturer’s guidelines. To 
improve the detection of low-expressing miR targets, 
the cDNA was then amplified using universal miR-Amp 
primers of the latter kit. Nucleic acid concentration 
was measured by NanoDrop 1000 Spectrophotometer 
(Thermo Fisher Scientific, Waltham, MA, USA).
MiR expression measurements in discovery and validation 
cohorts
A selection of potential miR marker candidates for CNS 
leukemia was obtained by compiling miRs expressed in 
(i) BM cells under leukemic conditions, (ii) blast cells 
with distinct genetic features and (iii) human platelets to 
rule out sample mistreatment, as previously described 
[18]. This process resulted in 47 candidate miRs selected 
for profiling, see Additional file 1: Table S2. The expres-
sion of candidates was measured by quantitative poly-
merase chain reactions (qPCR) performed on Custom 
TaqMan Advanced Low-Density Array (TLDA) micro-
fluidic cards (Thermo Fisher Scientific, Waltham, MA, 
USA), according to the manufacturer’s description using 
QuantStudio 7 Flex Real-Time PCR System (Thermo 
Fisher Scientific, Waltham, MA, USA). As a second 
step, identified differentially expressed  (CNS+ vs.  CNS‒ 
groups) miR candidates were assessed in the validation 
cohort. This qPCR verification was carried out on the 
7900HT Fast Real-Time PCR System (Thermo Fisher Sci-
entific, Waltham, MA, USA). The experiments were per-
formed in duplicates using TaqMan Advanced miRNA 
Assays and TaqMan Fast Advanced Master Mix (Thermo 
Fisher Scientific, Waltham, MA, USA) following the 
manufacturer’s instructions.
Cel-miR-39 (synthesized with 5′-phosphates; Assay ID: 
000200) was added as a non-human spike-in control to 
samples during RNA isolation. After the qPCR reactions, 
all amplification curves were inspected regardless to 
patients’ CNS status in order to exclude nonspecific arte-
facts. The expression fold change value was calculated 
according to the comparative cycle threshold (Ct) algo-
rithm for each sample. In the validation analysis, at each 
miR under the detection level, missing Ct values were 
replaced with maximum Ct per assay, except for normal-
izer miR.
Determination of CSF EV characteristics
To evaluate small EV density, firstly,  CD63+ EVs were 
isolated from CSF samples after centrifuging at 300g for 
5 min and 2000g for 20 min. EVs were bound by adding 
10  μl anti-CD63-coated beads (Exosome-Human CD63 
Isolation/Detection Reagent, Thermo Fisher Scientific, 
Waltham, MA, USA) prepared according to the manufac-
turer’s instructions to 300 μl supernatant. After overnight 
incubation with mixing at 4 °C, beads were magnetically 
separated (DynaMag Spin Magnet, Thermo Fisher Scien-
tific, Waltham, MA, USA), washed with PBS and beads 
were labelled with anti-CD63-PE (SAB4700218, Sigma-
Aldrich) for 20 min. Up to 5000 beads were then meas-
ured on a FACSCalibur (BD Biosciences, San Jose, CA, 
USA) instrument. Output was analyzed using FlowJo 
software (FlowJo LLC, Ashland, OR, USA; version: 
10.5.3).
In another experiment, small EV-rich fractions (irre-
spective of the presence of CD63) were isolated for 
further analysis according to the directives of the Inter-
national Society for Extracellular Vesicles [19]. Briefly, 
CSF was centrifuged in order to remove large cell debris 
(300g for 5 min) and pelleting of large, secreted microves-
icles from the cell-free supernatant (12,500g for 20 min). 
A collection of small EVs was performed with two rounds 
of ultracentrifugation (UC) at 100,000g for 70 min at 4 °C, 
completed with a washing step using PBS between the 
UCs. Finally, the pellet was resuspended in 60 µl PBS. A 
3 µl droplet was dried on a formvar-coated 300 mesh Ni 
grid (SPI Supplies, USA) for 10 min. The residual liquid 
was removed and samples were processed for immuno-
electron microscopy with anti-CD63 and anti-CD81 anti-
bodies, simultaneously, following previously described 
steps [20]. Sample examination was carried out using 
JEOL 1011 transmission electron microscope (Tokyo, 
Japan).
Bioinformatic analysis
The R language and environment for statistical comput-
ing and graphics was used for bioinformatic analysis 
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(R Foundation for Statistical Computing, Vienna, Aus-
tria; version 3.5.3). Selection of miRs for normalization 
purposes was performed using geNorm [21] and Nor-
mFinder [22] algorithms. MiR with probable uniform 
expression levels in all study samples and a satisfactory 
abundance in CSF and PB was accepted as reference miR. 
Principal component analysis (PCA) with FactoMineR 
package [23] was used for exploratory multivariate data 
investigation in the discovery study. PCA helped distin-
guish between CSF samples with  CNS+ or  CNS− back-
ground based on miRNomic profile and select candidate 
miRs for further examinations. Empirical Bayes statisti-
cal tests with false discovery rate (FDR) adjustment were 
performed using the limma package [24] for the evalua-
tion of differential miR expression in the validation study. 
All linear models were adjusted for age at diagnosis and 
gender. To determine the diagnostic accuracy of promis-
ing markers, area under the receiver operating character-
istic (ROC) curve and predictive values were defined by 
pROC package. Alpha level of 0.05 was used as criterion 
for statistical significance after FDR correction. The data-
sets used and analysed during the current study as well 
as full analysis code are available from the corresponding 
author on reasonable request.
Results
Differences in CSF microRNA expression between  CNS+ 
and  CNS‒ patients of the discovery cohort
Firstly, we examined whether microRNAs (miRs) were 
detectable in frozen cerebrospinal fluid (CSF) samples, 
collected from patients of the discovery cohort. Inter-
estingly, in direct measurements with the use of a spec-
trophotometer, the concentration of unamplified cDNA 
prepared from total miR was slightly higher in  CNS‒ 
patients than in the  CNS+ group (mean ± standard error: 
1222.3 ± 19.4 in  CNS− group vs. 1126.8 ± 9.1 in  CNS+ 
group; p = 0.002).
We used TLDA cards to screen the miR profile of CSF 
samples derived from patients with precursor B-cell ALL 
(pB-ALL) and peripheral blood (PB) samples of non-leu-
kemic control individuals, respectively. In 83% of miRs, 
the standard error (SE) of the average Ct values in sam-
ple duplicates remained under 2 (range: 0.05‒4.69). Three 
(miR-106a-5p, miR-383-5p, miR-654-5p) of the 47 miRs 
were not detectable in any of the CSF samples. MiR 
expression measurements by TLDA cards identified miR-
532-5p as the most stably expressed miR in collective 
examination of CSF and PB samples. Thus, miR-532-5p 
was assigned as reference miR and mean relative CSF 
gene expressions was calculated relative to the reference 
PB samples. All miRs were quantified at two different 
treatment checkpoints: (i) at diagnosis in both  CNS+ and 
 CNS− patient groups and (ii) on the 15th follow-up day 
in  CNS+ patients, see Fig. 1a.
Expression fold changes (relative to normalizer miR) 
of each miR in each sample were evaluated by princi-
pal component analysis (PCA) with a goal of identifying 
miRs that could potentially influence the classification 
of the patients by their CNS status. It was observed that 
three members of the miR-181-family (miR-181a-5p, 
miR-181b-5p, miR-181c-5p) had consistent and consider-
able positive contributions to all the first three principal 
components (PCs) and their aggregated contributions 
were above the expected average cut-off value (Addi-
tional file 1: Table S3). The first three PCs are included to 
reach a total sum of at least 70% of the original variation 
(PC1: 36.8%; PC2: 22.9%; PC3: 16.4%). The PCA biplot of 
PC1 and PC2 (Fig.  1b) shows the clusters of  CNS+ and 
 CNS‒ diagnostic samples with clustering performed at 
a confidence interval of 95%. Small angles between the 
miR-181-family members on loading plot of PC1 and 
PC2 (Fig. 1b) imply strong positive pairwise correlations.
A decrease in CSF miR levels to the 15th day of the 
treatment was also found in  CNS+ patients. Among all 
tested RNAs, levels of miR-181a-5p, miR-181b-5p and 
miR-181c-5p showed the strongest reductions, as their 
expression fold changes (ΔFC) were 36.2, 299.4 and 39.8 
times lower than at the diagnosis, respectively (see more 
information in Additional file 1: Table S4). In accordance 
with the previously mentioned results, miR-181a-5p and 
miR-181b-5p were selected for further validation.
Diagnosis of CNS leukemia on the basis of miR‑181a‑5p 
level in CSF of patients with ALL
Relying on the TLDA card-based findings, two candidate 
markers (miR-181a-5p, miR-181b-5p) were tested using 
CSF samples in the validation cohort consisted of lym-
phoid, myeloid and mixed phenotype acute leukemia. We 
were able to confirm the high expression of miR-181a-5p 
in diagnostic CSF samples in a partly independent set 
of 8  CNS+ ALL patients compared with 10  CNS− ALL 
patients by conventional qPCR, see Fig.  2a. However, 
similar results were not found when also including AML 
patients to the analysis. In those patients with ALL, 
miR-181a-5p expression levels conferred a more than 
52-fold increased risk for CNS leukemia  (CNS+ vs.  CNS− 
patients: ΔFC = 52.30, p = 1.49E−4). MiR-181a-5p rela-
tive expression level in CSF were independent of B- or 
T-cell immunophenotypes of ALL. Patients with overt 
CSF blastosis (CSF with a cell count of > 5/μl and blasts 
in excess on the cytospin slide) had the most outstanding 
miR-181a-5p expressions within the  CNS+ ALL group. 
Median miR-181a-5p expression in ALL patients with-
out CNS leukemia did not reach the median miR level 
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detected in reference CSF samples collected from SMA 
patients (Fig.  2a). There were no significant expression 
differences in the case of miR-181b-5p in the validation 
cohort.
Regarding ALL patients in the validation cohort, the 
diagnostic efficacy of miR-181a-5p in CSF was evaluated 
by receiver operating characteristic (ROC) method. This 
novel marker yielded a sensitivity of 90.0% and specific-
ity of 87.5% (area under the ROC curve, AUC: 92.5%) 
for CNS disease at a cut-off ΔFC value of 3.7, as shown 
in Additional file  2: Figure S1. To compare the clinical 
applicability of this miR marker with conventional cyto-
morphology technique, the latter one was also assessed 
based on previous reports [25] and signed as a ROC-
curve in Additional file 2: Figure S1.
To address the issue of treatment-induced alteration 
dynamics of miR expression in time, we determined the 
miR-181a-5p expression level in CSF samples of ALL 
patients during the induction chemotherapy. MiR levels 
were measured at three timepoints: at diagnosis (before 
any drug administration), on the 15th day of therapy 
and on the 33rd day of therapy. We managed to obtain 
CNS─ CSF at diagnosis
CNS+ CSF at diagnosis
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Fig. 1 MiR-181-family has consistent contribution to altered microRNA expression in cerebrospinal fluid samples in discovery cohort. a Heatmap 
shows the overexpressed (red) and the downregulated (blue) microRNAs (miRs) in distinct sample types. Gross divergence in miR pattern of 
patients with or without initial CNS disease is highlighted with black frames. Mean relative expression levels were determined by ddCt algorithm, 
using miR-532-5p as reference miR and PB samples of control individuals as reference samples. b Biplot derived from principle component analysis 
shows clusters of CNS-positive and CNS-negative diagnostic samples at a confidence level of 95%. Corresponding loading plot (vectors) displays 
miR-181-family members. The cosine between two vectors approximates the correlation between miR variables. Position of vectors indicates 
considerable positive contributions to first and second principal component. CNS central nervous system, CSF cerebrospinal fluid, ddCt delta–delta 
Ct, miR microRNA, PC principal component
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an extra sample from a patient (P2) with massive CNS 
involvement at 45th day of therapy and samples at excep-
tional therapy days (15th, 26th and 40th) from a patient 
(P12) with fatal disease course. Figure 2b shows changes 
in relative expression level of CSF miR-181a-5p in  CNS+ 
and  CNS− ALL groups and, separately, in patient P12. 
The average level of miR-181a-5p decreased by 96.7% 
among  CNS+ patients (P12 was excluded from this analy-
sis) to the 33rd day of therapy, while it remained around 
the expression detected in diagnostic sample at our later 
time points in patients without CNS leukemia. Interest-
ingly, patient P12′s miR-181a-5p expression has risen 
in parallel with clinically observed disease progression. 
Patient P12 could not finish the induction chemotherapy 
and was treated in intensive care unit until death. In a 
patient with  CNS+ relapse (P1, ΔFC = 2.40) we observed 
a more than twofold rise in miR-181a-5p expression to 
the 15th treatment day from the initial level. This change 
was not seen in relapsed patients with blast-free CSF 
(P17 and P18; ΔFC = 0.06 and ΔFC = 0.83, respectively).
Inferiority of bone marrow and peripheral blood 
miR‑181‑family expression to indicate CNS status in ALL
We studied whether the expression levels of miR-181a-5p 
and miR-181b-5p in PB and BM samples could provide 
diagnostic or predictive information on CNS leukemia 
involvement. Initial PB miR-181a-5p level significantly 
fell down to the15th and to the 33rd day of treatment 
in ALL patients regardless of CNS status (to day 15: 
ΔFC = − 6.42, p = 0.02; to day 33: ΔFC = 7.95, p = 0.03). 
However, there was no difference in miR-181a-5p expres-
sion at diagnosis between  CNS+ and  CNS‒ ALL groups 
in PB.
MiR-181a-5p expression levels in BM highly exceeded 
corresponding CSF expression in  CNS‒ ALL patients at 
the diagnosis (ΔFC = 21.97, p = 0.007), but there was no 
such relation in the  CNS+ group. Initial BM expression 
of miR-181a-5p distinguished only those patients with 
 CNS+ and  CNS− ALL who were characterized by pre-
cursor B-cell immunophenotype (ΔFC = 9.18, p = 0.04). 
However, miR-181a-5p level in PB of control individu-
als was lower than in BM of pB-ALL patients in both 
CNS status groups  (CNS+ status: ΔFC = 55.82, p = 0.001; 
 CNS‒ status: ΔFC = 6.08, p = 0.04). Decrease in miR-
181a-5p level from the diagnosis of ALL to the 33rd day 
of therapy was also detectable in BM samples not only 
among  CNS+ patients (ΔFC = − 187.96, p = 0.006), but 
also in the  CNS− group (ΔFC = − 8.54, p = 0.002).
a b
Fig. 2 MiR-181a-5p level is a central nervous system involvement indicator in pediatric acute lymphoblastic leukemia. a Each dot indicates the 
miR-181a-5p expression of a patient. Horizontal line in box plots represents median fold change (FC), extent of boxes indicates upper and lower 
quartiles, whiskers show maximum and minimum values. b Lines are dedicated to follow the FC alterations in patient groups with and without 
meningeal leukemia and in a highlighted patient with progressive disease course during induction chemotherapy. Points indicate average FC 
values, while whiskers mark standard errors. CSF cerebrospinal fluid, CNS central nervous system, SMA spinal muscular atrophy, ΔFC difference in fold 
change
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Atypical small extracellular vesicles in CSF of ALL patients 
with CNS involvement
Whether extracellular vesicle (EV) production from par-
ameningeal leukemic infiltration can be demonstrated by 
CSF sampling is not yet known. Immunomagnetic bead 
separation technique was applied to compare the number 
of  CD63+ particles (typically endosome-derived small 
EVs) in CSF samples of  CNS+ and  CNS‒ ALL patients 
(n = 2 and n = 2, respectively). Their measurable amount 
was very low and no difference was found in the propor-
tion of  CD63+ beads (mean ± SE: 1.0 ± 0.2% in  CNS+ 
group vs. 1.1 ± 0.1% in  CNS− group). Next, from both 
 CNS+ and  CNS− patient groups, a representative pB-
ALL and a representative T-ALL CSF sample processed 
by ultracentrifugation (nonselective for cluster of differ-
entiation markers) were supervised by immunolabelling 
for CD63 and CD81 markers using transmission electron 
microscopy (TEM). Interestingly, a considerable differ-
ence was observed in the density of vesicular elements 
between  CNS+ and  CNS− patients, as shown in Fig.  3. 
High amount of EVs in the  CNS+ pB-ALL sample mostly 
showed  CD63‒/CD81− characteristics (Fig.  3a). Whilst, 
there were low number of EVs in the  CNS− pB-ALL sam-
ple (Fig. 3b). CSF samples of T-ALL cases showed quite 
similar pattern, but in this immunophenotype group we 
found a  CD63−/CD81− conglomerate of EVs in the  CNS− 
sample as well (Fig. 3c, d). Presence of  CD63+ and  CD81+ 
small EVs in CSF, even if a low number, were confirmed 
in both CNS groups and immunophenotypes.
Discussion
Contrary to the overall survival rate of 70–85% among 
children with acute leukemia, leukemic infiltration of the 
central nervous system (CNS) niche is associated with 
relapses and major therapeutic obstacles [2]. We still 
lack methods to follow up CNS leukemia with appro-
priate sensitivity. There are two major clinical enigmas 
related to CNS disease: (i) how can we better screen 
occult meningeal leukemia and thereby prescribe ade-
quate CNS-directed treatment for those who need it, and 
(ii) may we apply novel molecularly targeted therapies 
against CNS infiltration in the era of precision oncology? 
It is also not fully understood whether the initial CNS 
leukemia burden or its dynamics during treatment have 
more prognostic value.
Here we proposed a potential biomarker for the CNS 
status in ALL. Cerebrospinal fluid (CSF) miR-181a-5p 
expression levels were unexpectedly high in patients 
with cytologically confirmed  CNS+ ALL, while levels 
in those lacking meningeal involvement were measured 
around control levels. This result originated from a dis-
covery screening of 47 candidate miRs and was validated 
in an extended, but still limited study set. Similarly, a 
considerable difference was observed in the density of 
small vesicular elements in CSF samples of  CNS+ and 
 CNS‒ patients with ALL. To date, only one study has 
reported that miRs can be measured in the CSF collected 
from children with leukemia [26]. Furthermore, our 
study is unique in that miR expression alterations can be 
followed individually in time thanks to the serial sample 
collection, and miR patterns in different compartments 
of sampling can be compared. CSF-based EV studies in 
leukemia are also in their early infancy.
Despite the omnipresence of ribonucleases, miRs were 
found to be highly stable in all body fluids, hence, could 
be utilized as clinical biomarkers [27]. MiR-181a serves 
as a regulator of normal hematopoiesis and its disrup-
tion has been linked to various types of cancer, includ-
ing hematological malignancies [28]. It is one of the most 
abundant miRs in lymphocytes [29]. In acute leukemia, 
the exact role of miR-181a is still unclear as contradicting 
papers claim its oncogene as well as tumor suppressor 
effects [30–33]. Besides, several mechanisms spreading 
to the CNS by ALL cells have been revealed recently and 
can be influenced by miR-181a regulatory actions. Of 
particular interest to our findings, overexpression of vas-
cular endothelial growth factor A (VEGFA), a miR-181a 
regulated hypoxia-responsive gene, proved to provide 
survival advantage to CNS-penetrating ALL cells in the 
hypoxic, nutrient-poor microenvironment of the CNS. 
This phenomenon was described in both primary pre-B 
ALL cells isolated from the CSF of children with CNS 
involvement and a mouse primograft model for  CNS+ 
ALL [34–36]. The positive correlation between the miR-
181a expression and VEGFA production in a non-epithe-
lial tumor tissue was proposed through the scrutiny of 
human chondrosarcoma cells [37]. A detailed explana-
tion how miR-181a promotes the SRC/VEGF signaling 
pathway was shown in preclinical models of colorectal 
cancer [38]. A similar mechanism might work in ALL, 
too. Yet, the nature of CNS disease evolution is not fully 
understood. While the VEGFA mechanism suggests 
increased vascular permeability and reduced barrier 
function of endothelium to make cell migration possible 
into the CNS, a novel study claims that the whole pro-
cess happens abluminally, along emissary bridging vessels 
based on integrin alpha-6 (ITGA6)-laminin interaction 
[39]. Interestingly, ITGA6 may interact with miR-181a 
according to the mirDIP v4.1 integrative miR target pre-
dictor database [40].
Whether the ability to invade the CNS is a generic 
property of all ALL blasts or only a subpopulation of 
cells can selectively enter this compartment is a sub-
ject of recent debate. We found that bone marrow (BM) 
miR-181a-5p expression of  CNS‒ patients (i) exceeded 
the average level of  CNS− CSF and control samples and 












Fig. 3 Atypical extracellular vesicles in cerebrospinal fluid of patients with different central nervous system (CNS) status. a Transmission electron 
microscopy (TEM) images of a cerebrospinal fluid (CSF) sample from a  CNS+ patient with precursor B-cell acute lymphoblastic leukemia (pB-ALL) 
depict several small extracellular vesicles (EVs). Inserted panels show the absence of CD63/CD81 immunogold labelling which is a key feature of 
these EVs. b TEM images taken from the CSF sample of a patient with  CNS‒ pB-ALL. Appearance of gold particles refer to CD63 (10 nm) and CD81 
(5 nm) positivity of the EVs. c Small EVs in a patient with relapsed  CNS+ T-cell ALL show mainly the absence of CD63/CD81 immunogold labelling. 
d  CD63+/CD81+ small EVs in CSF from a patient with T-cell ALL without CNS involvement. Conversely, inserted slide shows a conglomerate of EVs 
without typical markers of exosomes originating from multivesicular body
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(ii) responded to the chemotherapy with significant 
reduction, similarly to the  CNS+ BM samples. Thus, 
our data tend to support the theory that ALL cells in 
the BM compartment have a common ability to reach 
meningeal surfaces, as previously proposed [41, 42]. 
Also, the seeding of CNS leukemia may depend on a 
dynamic relationship between extramedullary micro-
environment and blast cells which is influenced by 
regulatory elements (e.g. miR-181a), rather than prede-
termined cell-intrinsic and clone-specific ‘CNS-tropic’ 
features (e.g. cell surface protein composition). Basi-
cally, it was out of our aims to identify the cellular ori-
gin of miR-181a-5p in this study setting. Yet, there are 
some points which suggest the examination of leukemic 
blasts as potential miR-181 secretors: (i) miR-181a is 
a well-known small RNA produced by lymphoid cells 
[29]; (ii) miR-181a was found in significant amount in 
blast-rich BM samples, regardless of CNS status; (iii) 
in  CNS− CSF samples, where blasts were absent, the 
average expression of miR-181a was very low. How-
ever, it is also a possibility that miR-181a originates 
from non-leukemic cells communicating with leukemic 
blasts (e.g. stromal cells in BM or resident cells in CNS 
leukemic niche) and we measured this phenomenon 
in our samples. There are plenty of evidence that miR-
181-family plays role in the modulation of tissue dif-
ferentiation, remodeling and degeneration in the CNS, 
moreover, it has anti-inflammatory effect in the context 
of neuroinflammation [43].
According to our data, miR-181a-5p may provide about 
35% sensitivity benefit compared to the cytospin method 
when diagnosing ALL infiltration in the CNS at the ini-
tiation of chemotherapy. However, a paper described that 
occult meningeal disease during therapy resulted in sig-
nificantly higher rates of relapses and death in pediatric 
ALL, while no such influences were found with initial 
CSF evaluation [44]. Thus, the alteration of initial miR-
181a-5p level might be considered to estimate prognosis.
Candidate miR expression analysis of peripheral 
blood (PB) samples identified no benefit of measuring 
miR-181-family levels to diagnose CNS involvement. In 
contrast, we showed the possible role of diagnostic BM 
miR-181a-5p expression in determining CNS status, 
however, it was demonstrated solely in pB-ALL patients. 
This finding might propose a less invasive alternative to 
LP as BM aspiration which is sometimes also performed 
at CSF sampling time points. However, higher BM miR-
181a-5p level may be associated with general miRNomic 
disturbance under leukemic conditions as  CNS‒ patients 
showed elevated relative expression as well. We rather 
prefer the investigation of miR-181a-5p level alteration 
in time as it may monitor the CNS-attacking blast capac-
ity of the BM compartment. To indicate subsequent 
CNS relapse by BM examination, others identified cel-
lular proteins [45] and miR pattern [46] in BM cells of 
ALL patients, but venipuncture-based CNS involvement 
markers were not published.
This is the first study in which small extracellular 
vesicle (EV) composition of CSF was assessed in rela-
tion with CNS disease state in acute leukemia patients. 
Atypical small EVs were found in unexpectedly high den-
sity in  CNS+ diagnostic CSF samples. The phenotype of 
these vesicles is not fully understood. They were nega-
tive for CD63 and CD81, which contradict the multive-
sicular body origin [47]. Nonexosomal subpopulation of 
small EVs was previously demonstrated [48], and most 
of the EVs in  CNS+ CSF reached the lower limit of the 
microvesicle size range. Otherwise, it is unlikely that 
these bodies are lipoproteins with EV-like appearance as 
CSF lipoprotein content is minimal [49].
In summary, our data represent the first description 
of a miR as possible CNS infiltration marker in pediatric 
ALL and extends our knowledge about a small EV sub-
group that may associate with  CNS+ status. However, 
several limitations should be noted when interpreting 
our results. Since CNS involvement is a rare condition 
in childhood leukemia, the difficulty of obtaining  CNS+ 
samples resulted in low patient numbers. Our results 
should be verified in larger cohorts before concluding any 
practical benefit. Another bias is the selection of patients 
with and without the meningeal disease, which relied on 
the insensitive conventional cytologic assessment tools. 
Yet, this study provides the rationale for future investi-
gations of miRs in the CSF for diagnostic and prognos-
tic purposes. Our results encourage further research 
regarding the targeted therapy of CNS leukemia [35, 36] 
or miR-181a-based therapeutics as seen in lung cancer 
models in vitro [50].
Conclusions
Disease course indicators are the “Achilles heel” of ther-
apy success in pediatric ALL and miR-181a-5p expression 
in CSF may provide potential new tools for this purpose. 
Based on our experiments, it can worth to further exam-
ine miR-181a-5p level in CSF as highly sensitive and spe-
cific CNS involvement indicator in ALL to find a novel 
approach which can upgrade contemporary diagnostic 
methods. Moreover, with our very first experiments, we 
propose further CSF small EV measurements and char-
acterization from CNS leukemia perspective.
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